A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone

Clinical Therapeutics

Volumn 25, Issue 6, 2003, Pages 1618-1633

  Robinson, Donald S ^a,d   Ad Sitsen, J M ^b   Gibertini, Michael ^c  

^a Worldwide Drug Development Melbourne   (United States)

^b NV ORGANON   (Netherlands)

^c Organon Pharmaceuticals USA Inc   (United States)

^d NONE   (United States)

Author keywords

Gepirone; Major depressive disorder; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; GEPIRONE; IMIPRAMINE; PLACEBO; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DROWSINESS; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EXTENDED RELEASE FORMULATION; GASTROINTESTINAL SYMPTOM; GENERAL CONDITION IMPROVEMENT; HAMILTON SCALE; HEADACHE; HUMAN; IMMEDIATE RELEASE FORMULATION; INSOMNIA; MAJOR DEPRESSION; MEDLINE; NAUSEA; PARESTHESIA; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TABLET; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; VERTIGO; VISUAL IMPAIRMENT; VIVID DREAM;

EID: 0038721597     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80159-5     Document Type: Review

References (30)

1. 1A receptor agonists as antidepressants: Pharmacological rationale and evidence for efficacy. CNS Drugs. 1998;10:343-353.
2. Fitton A, Benfield P. Gepirone in depression and anxiety disorders: An initial appraisal of its clinical potential. CNS Drugs. 1994;1:388-398.
3. 1A agonists. A comparative review. CNS Drugs. 1994;2:234-251.
4. Timmer CJ, Sitsen JM. Pharmacokinetics of extended-release and immediate-release gepirone in healthy volunteers. J Pharm Sci. In press.
5. 1A agonists correlates with dopamine antagonist properties. J Pharmacol Exp Ther. 1994;268:1297-1303.
6. Hamik A, Oksenberg D, Fischette CT, Peroutka SJ. Analysis of tandosporine (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry. 1990;28:99-109.
7. 1A agonists in the treatment of depression? Biol Psychiatry. 2003;53:193-203.
8. 1A agonist gepirone: Electrophysiological studies in the rat brain. Synapse. 1987;1:470-480.
9. 1A agonists. In: Stahl SM, ed. Serotonin 1A Receptors in Depression and Anxiety. New York: Raven Press, Ltd; 1992:83-97.
10. Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology. 1999;21(Suppl 2):91S-98S.
11. Gartside SE, Umbers V, Hajos M, Sharp T. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: Effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol. 1995;115:1064-1070.
12. 1A receptor agonists. J Cardiovasc Pharmacol. 1990;15(Suppl 7):S42-S48.
13. 1A receptors. J Neurosci. 1998;18:10150-10156.
14. Bianchi G, Garattini S. Blockade of alpha 2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone. Eur J Pharmacol. 1988;147:343-350.
15. Abe M, Tabata R, Saito K, et al. Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models. J Pharmacol Exp Ther. 1996;278:898-905.
16. Redrobe JP, Bourin M. Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psychopharmacology (Berl). 1998;138:198-206.
17. Tay LK, Sciacca MA, Sostrin MB, et al. Effect of food on the bioavailability of gepirone in humans. J Clin Pharmacol. 1993;33:631-635.
18. Tay LK, Dixon F Jr, Sostrin MB, et al. The site of gastrointestinal absorption of gepirone in humans. J Clin Pharmacol. 1992;32:827-832.
19. Feiger AD, Heiser JF, Shrivastava RK, et al. Gepirone extended-release: New evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry. 2003;64:243-249.
20. Ruwe F, Gibertini M, Sitsen JM, et al. Relapse prevention with gepirone-ER in outpatients with major depression. Poster presented at: American College of Neuropsychopharmacology Annual Meeting; December 8-12, 2002; San Juan, Puerto Rico.
21. 1A agonist in the treatment of major depression. Psychopharmacol Bull. 1990;26:169-171.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
23. Jenkins SW, Robinson DS, Fabre LF Jr, et al. Gepirone in the treatment of major depression. J Clin Psychopharmacol. 1990;10(Suppl 3):77S-85S.
24. Amsterdam JD. Relapse prevention during long-term gepirone therapy for major depression. Paper presented at: 154th American Psychiatric Association Annual Meeting; May 5-10, 2001; New Orleans, La.
25. Guy W, ed. Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Department of Health and Human Services, Public Health, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch; 1976:218-222.
26. Wilcox CS, Ferguson JM, Dale JL, Heiser JF. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull. 1996;32:335-342.
27. Bech P. Psychometric developments of the Hamilton scales: The spectrum of depression, dysthymia, and anxiety. Psychopharmacol Ser. 1990;9:72-79.
28. Feiger AD. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull. 1996;32:659-665.
29. McGrath PJ, Stewart JW, Janal MN, et al. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry. 2000;157:344-350.
30. McGrath PJ, Stewart JW, Quitkin FM, et al. Gepirone treatment of atypical depression: Preliminary evidence of serotonergic involvement. J Clin Psychopharmacol. 1994;14:347-352.